With a collective head smack last week, pharma industry digital insiders read about WebMD’s decision to pursue a sale or merger after some reports blamed the move on slowing pharma spending on digital marketing. That’s because just the opposite seems true based on a wide swath of reports, data and predictions. A digital marketing pullback would go against both forecasts and the intent declared intent by pharma companies themselves.
